

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

10261

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br>A61K 38/00, 38/04, 39/00, 39/108,<br>39/385, C07K 9/00, 14/245, 17/00, 19/00                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | <b>A1</b> | <b>(11) International Publication Number:</b> WO 95/31994<br><b>(43) International Publication Date:</b> 30 November 1995 (30.11.95)                                                                                                                                                                                                                                                                                                                                                               |
| <b>(21) International Application Number:</b> PCT/US95/06575<br><b>(22) International Filing Date:</b> 24 May 1995 (24.05.95)<br><b>(30) Priority Data:</b><br>109790 25 May 1994 (25.05.94) IL<br><b>(71) Applicant (for all designated States except US):</b> YEDA RE-<br>SEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; The<br>Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot<br>(IL).<br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> COHEN, Irun, R. [US/IL];<br>11 Hankin Street, 76354 Rehovot (IL). FRIDKIN, Matityahu<br>[IL/IL]; 23 Miller Street, 76284 Rehovot (IL). KONEN-<br>WAISMAN, Stephanie [DE/IL]; 29 B Maaze Street, 65214<br>Tel Aviv (IL).<br><b>(74) Agents:</b> BALDWIN, Geraldine, F. et al.; Pennie & Edmonds,<br>1155 Avenue of the Americas, New York, NY 10036 (US). |           | <b>(81) Designated States:</b> AM, AU, BB, BG, BR, BY, CA, CN, CZ,<br>EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT,<br>LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD,<br>SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent<br>(AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC,<br>NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,<br>GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW,<br>SD, SZ, UG).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> PEPTIDES USED AS CARRIERS IN IMMUNOGENIC CONSTRUCTS SUITABLE FOR DEVELOPMENT OF SYNTHETIC<br>VACCINES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>(57) Abstract</b><br><br>The invention relates to conjugates of poorly immunogenic antigens, e.g., peptides, proteins and polysaccharides, with a synthetic peptide carrier constituting a T cell epitope derived from the sequence of <i>E. coli</i> hsp65 (GroEL), or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen. A suitable peptide according to the invention is Pep287e, which corresponds to positions 437-453 of the <i>E. coli</i> hsp65 molecule.                                                                                                                                                                                                                                                                              |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

AM4

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Larvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

LMA

**PEPTIDES USED AS CARRIERS IN IMMUNOGENIC  
CONSTRUCTS SUITABLE FOR DEVELOPMENT OF SYNTHETIC VACCINES**

**FIELD OF THE INVENTION**

5           A synthetic peptide, is described having an amino acid sequence corresponding to that of a T cell epitope of the heat shock protein 65 of *E. coli* (hereinafter GroEL) and its analogs able to be recognized in association with a range of mouse major histocompatibility complex (MHC) molecules.

10 Said peptide or its analogs can be used as synthetic carriers in the preparation of immunogenic conjugates consisting of said peptides and a natural or synthetic hapten derived from a pathogenic agent of interest.

15                           **BACKGROUND OF THE INVENTION**

          Immunization against infection caused by pathogenic microorganism (bacteria, viruses and parasites) is generally achieved by inoculating an individual with the natural antigen (attenuated or killed microorganism) or parts of said

20 infectious agent (for example detoxified microbial products) in order to stimulate a protective immune response able to neutralize the pathogenic microbe or its deleterious effects.

          Limited availability of the natural antigenic substance, risks involved in handling pathogenic material as

25 well as storage problems stimulated the interest in the development of subunit vaccines. Isolated protective epitopes nevertheless are often characterized by their poor immunogenicity. The carbohydrate capsules of bacteria are an example of such coats: They are not easily recognized by T

30 cells and therefore the immune response to these antigens is deprived of T cell help, T cell memory, IgG class switch, and affinity maturation. Such an immune response is inefficient and resistance to infection with bacteria encoated with carbohydrate capsules is not easily obtained by vaccination

35 with bacterial carbohydrates. Peptide epitopes too may be

poorly immunogenic, the absence of a T cell epitope and the genetically restricted immune response being the reason.

It is now well established that most antigens require T cell help to induce B cells to produce antibodies. 5 Conjugating a "helper" or T cell determinant to a B cell-specific antigen was shown to induce humoral immune responses to the coupled B cell epitope. The discovery by Avery & Goebel (1929) that coupling of polysaccharides to protein carriers increases immunogenicity has recently been used for 10 the preparation of vaccines for human use. Both in humans and in rodents these conjugates behave like T cell dependent antigens by exhibition of immunological memory. There are similarities between conjugate polysaccharide vaccines and protein carrier-hapten systems. Thus the capsular 15 polysaccharide (CPS) conjugates are able to induce protective levels of CPS antibodies in infants, while CPS alone is not. It is possible that the superior immunogenicity of conjugates compared to that of pure polysaccharides is due to the help by carrier-specific T cells, as has been demonstrated in the 20 carrier-hapten system in rodents.

In most cases, T cell independent (T-ind) antigens have been coupled to large immunogenic carrier proteins such as tetanus toxoid, cholera toxin or diphtheria toxoid. Nevertheless, besides dosage limitations and the risk of 25 sensitization to the carrier itself, as reported for tetanus toxoid, the immunological response to high molecular weight carrier molecules harboring stimulatory as well as suppressive T cell epitopes is not very predictable. It has been shown that the antibody response to a hapten coupled to 30 a carrier protein can also be inhibited when the recipient has been previously immunized with the unmodified protein. This phenomenon has been termed carrier-induced epitope suppression and was recently demonstrated to occur with a number of hapten-protein conjugates (Herzenberg & Tokuhisa, 35 1982). Since the development of more potent conjugate vaccines against a large number of extremely infectious organisms is still important, efforts are being made to

search for more appropriate carrier molecules providing the needed T cell epitopes. Universally immunogenic T cell epitopes, defined by specific peptides with sharply outlined immunological characteristics, might represent a new  
5 generation of such alternative molecules. T cell epitopes of various sorts have been used for this purpose before. However, to trigger a strong memory response when the host meets the infectious agent after vaccination, the T cell carrier epitope should be present along with the specific B  
10 cell epitope. This fact would seem to require that a different T cell carrier be used for each infectious agent. Highly abundant proteins well recognized by the immune system might be an appropriate source for peptides serving this purpose.

15 Studies using a wide variety of proteins, both those closely related to self and those phylogenetically distantly related, have shown that the majority of T cells are focused onto a few immunodominant epitopes with a minority responding to other, subdominant determinants. This  
20 hierarchy of determinant utilization by T cells could result from a combination of factors including differential affinities for the available MHC molecules, the diversity of the T cell repertoire, internal competition for MHC-binding sites and fine differences in processing (Babitt et al, 1985;  
25 Kappler et al, 1987; Brett et al, 1988)

Evidence is accumulating that proteins belonging to the family of heat shock proteins (hsp's) are major antigens of many pathogens (Young et al, 1988). Hsp's were first described and later named due to their production by cells  
30 exposed to sudden elevations in temperature. The hsp's include proteins of various molecular weights, including 20kD, 60kD, 65-68kD, 70kD, 90kD, 110kD, and others. It is now apparent that hsp's are induced in all cells by many different environmental insults, including oxidative injury,  
35 nutrient depletion and infection with intracellular pathogens; the hsp response enables the cell to survive under otherwise unfavorable conditions. Although cellular stress

increases the synthesis of hsp's, many hsp's are also constitutively expressed and play an essential role in normal cell function. The hsp response is ubiquitous throughout the pro- and eukaryotic kingdoms and hsp's belong to some of the 5 most conserved molecules.

Hsp65, as a representative member of the proteins belonging to the hsp family, can be considered to be a dominant antigen because infection or immunization with many different bacteria induces antibodies and T cells specific 10 for the hsp65 molecule (Young et al, 1988). In mice immunized with *Mycobacterium tuberculosis*, 20% of all T cells which respond to the bacterium, are specific for hsp65. Interestingly, T cells with reactivity to hsp65 have also been identified in normal healthy individuals lacking any 15 clinical signs of disease (Munk et al, 1988).

Lussow et al. (1990) showed that priming of mice with live *Mycobacterium tuberculosis* var.bovis (BCG) and immunization with the repetitive malaria synthetic peptide (NANP)<sub>40</sub>, conjugated to purified protein derivative (PPD), led 20 to the induction of high and long-lasting titers of anti-peptide IgG antibodies. Later on, Lussow et al. (1991) reported that the mycobacterial hsp65 as well as the hsp65 of *E. coli* (GroEL) acted as carrier molecules in mice, previously primed with BCG, for the induction of high and 25 long-lasting titers of IgG against the repetitive malaria synthetic peptide (NANP)<sub>40</sub>. Anti-peptide antibodies were induced when the malaria peptide, conjugated to the mycobacterial or *E. coli* hsp, was given in the absence of any adjuvants.

30 Barrios et al. (1992) have shown that mice immunized with peptides or oligosaccharides conjugated to the 70kD hsp produced high titers of IgG antibodies in the absence of any previous priming with BCG. The anti-peptide antibody response persisted for at least 1 year. This 35 adjuvant-free carrier effect of the 70kD hsp was T cell dependent, since no anti-peptide nor anti70kD IgG antibodies were induced in athymic nu/nu mice. Previous immunization of

mice with the 65kD or 70kD hsp did not have any negative effect on the induction of anti-peptide IgG antibodies after immunization with hsp-peptide conjugates in the absence of adjuvants. Furthermore, preimmunization with the 65kD hsp  
5 could substitute for BCG in providing an effective priming for the induction of anti-(NANP)<sub>40</sub> antibodies. The carrier effect of mycobacterial hsp65 and hsp70 for conjugated peptides was demonstrated also in non-human primates (Perraut et al, 1993).

10 It can be assumed that some T cell epitopes within the sequence of the bacterial hsp65 protein show immunodominance and are able to induce immunological memory, whereas others do not express privileged immunological recognition or are involved in the induction of autoimmune  
15 diseases. Distinguishing between functionally different T cell epitopes, binding to several different MHC molecules, may lead to the identification of universally immunogenic peptides, which can qualify as safe, defined, and potent alternatives for carrier molecules of T-ind antigens.

20 Israel Patent Application No. 102687 of the same applicants describes specific T cell epitopes of human hsp65, and analogs thereof, conjugated to poorly immunogenic molecules.

None of the above mentioned references describes  
25 specific T cell epitopes derived from the sequence of hsp65 of *E. coli* (GroEL) conjugated to poorly immunogenic molecules.

#### SUMMARY OF THE INVENTION

30 It is an object of the present invention to provide a method for enhancing the immunogenicity of poorly immunogenic antigen molecules, thus converting them to suitable antigens for immunization.

For this purpose, the present invention provides  
35 conjugates of a poorly immunogenic antigen and a synthetic peptide carrier constituting a T cell epitope derived from the sequence of *E. coli* hsp65 (GroEL) or an analog thereof,

said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen.

Any peptide, or analog thereof, derived from GroEL  
5 constituting a T cell epitope and able to increase  
substantially the immunogenicity cm the poorly immunogenic  
antigen, can be used in the invention.

A preferred peptide according to the invention, herein designated 278e, corresponds to positions 437-453 of the GroEL molecule, and has the sequence:

437 453  
N E D Q N V G I K V A L R A M E A

The poorly immunogenic antigen molecule may be a peptide, a polypeptide or a protein, e.g., a peptide derived from HIV virus or from malaria antigen, or a bacterial polysaccharide, e.g., capsular polysaccharides from *Haemophilus influenzae* type b, *Streptococcus pneumoniae*, *Neisseria meningitidis*, group B *Streptococci*, *E. coli* type K1, *Salmonella*, such as *Salmonella typhi*, etc.

The carrier peptide is covalently linked to the poorly immunogenic antigen molecule, either directly or through a spacer.

The invention further relates to vaccines  
25 comprising a conjugate of the invention or a mixture of the  
poorly immunogenic antigen and the suitable peptide carrier.

In another embodiment, the invention relates to a method of immunization of a mammalian host which comprises administering to said host an effective amount of a conjugate  
30 of the invention, or co-administering effective amounts of a poorly immunogenic antigen molecule and of a synthetic peptide carrier constituting a T cell epitope derived from the sequence of GroEL, or an analog thereof, said peptide or analog being able to enhance substantially the immunogenicity  
35 of the poorly immunogenic antigen.



BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows lymph node proliferation to 278 epitopes 278e, 278m and 278cox after immunizing BALB/C mice with 20  $\mu$ g 278 epitope emulsified in incomplete Freund's 5 adjuvant (IFA).

Figs. 2a-c show lymph node proliferation to 278e and to control peptide ACR 259-271 after immunizing B10RIII mice (2a), B10.BR mice (2b), and B10.S mice (2c) with 20  $\mu$ g 278e emulsified in IFA.

10 Fig. 3 illustrates lymph node proliferation to peptides 278e, 278m, and Acr259-271 after immunizing BALB/c mice with 2 $\mu$ g Vi-fragments conjugated to 278 homologous or with 2 $\mu$ g Vi-fragments alone.

Fig. 4 illustrates lymph node proliferation to 15 peptides 278e, 278m, and Acr259-271 after immunizing BALB/c mice with 20  $\mu$ g Vi-fragments conjugated to 278 homologous or with 2 $\mu$ g Vi-fragments alone.

Fig. 5 shows the serum anti-Vi IgG antibody response induced in BALB/c mice by Vi-fragments alone or Vi- 20 fragment-conjugates 278h-Vi, 278m-Vi, and 278e-Vi. The injected polysaccharide amount in each group was 2 $\mu$ g. Primary and secondary immune responses are depicted. Results are shown at a serum dilution 1:100.

25 DETAILED DESCRIPTION OF THE INVENTION

Preferred conjugates according to the invention are formed by covalently linking peptide 278e with a bacterial polysaccharide, e.g., the capsular polysaccharide (CPS) Vi of Salmonella typhi, hereinafter referred to as Vi 30 or Vi-fragments, a linear homopolymer of poly- $\alpha$ -(1-4)GalNAc variably O-acetylated at the C<sub>3</sub>-position, as shown in scheme 1. The native Vi molecule has a molecular weight of about  $3 \times 10^3$  kD (Vi). Vi-fragments (about 45kD) are prepared by ultrasonic cleavage, which does not alter the structure of 35 its monomeric units and which produces a relatively homogeneous polysaccharide (Stone & Szu, 1988). Vi/Vi-fragments alone, like other CPSs, do not elicit a booster

response in mammals, either in animals or in humans, when reinjected, but its immunogenicity is increased when presented as a conjugate according to the invention coupled to a suitable peptide derived from GroEL or an analog

5 thereof, or in a mixture with such a peptide or analog.

Reinjection of the Vi-peptide conjugate induces an increase in the level of anti-Vi antibodies (booster effect), which are mainly represented by the IgG isotype.

Peptide 278e of the present invention is clearly  
10 distinct from peptides 278h and 278m of above-mentioned Patent Application No. 102687.

|      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 278e | N | E | D | Q | N | V | G | I | K | V | A | L | R | A | M | E | A |
| 278h | N | E | D | Q | K | I | G | I | E | I | I | K | R | T | L | K | I |
| 278m | N | E | D | Q | K | I | G | I | E | I | I | K | R | A | L | K | I |

15

Peptide 278e is a highly charged and hydrophobic molecule. Thus, 5 out of 17 constituent amino acids are ionized (3 negatively and 2 positively) at physiological pH. Five amino acid residues are hydrophobic. In addition, 3  
20 residues are amidated and capable of establishing substantial hydrogen bonding. The peptide is further characterized as possessing a polar negatively-charged N-terminal domain, a polar charged C-terminal domain and a highly hydrophobic core. 278e can be modified while retaining activity. In  
25 order to preserve activity, however, its overall structural features should be maintained. Thus, positions 2, 3 and 16 can be either occupied by either E or D, and positions 9 and 13 by either K or R. Conservation of the charge at positions 9 and 13 (positive to negative and vice-versa) will lead to  
30 active peptides. A hydrogen bond forming amino acid, preferably N and Q, should occupy positions 1 and 4.

Hydrophobicity at positions 6, 8, 10, 12 and 15 should be maintained by incorporating hydrophobic amino acids, natural, e.g., I, L, V, M or F, or unnatural, e.g.,  
35 norleucine (Nle) or norvaline (Nva).

The term "analogs" in the present invention relates to peptides obtained by replacement, deletion or addition of


amino acid residues to the sequence of the T cell epitope, as long as they have the capability of enhancing substantially the immunogenicity of poorly immunogenic antigen molecules. Analogs, in the case of peptide 278e, are peptides such that  
 5 at least 70%, preferably 90-100%, of the electric properties and of the hydrophobicity of the peptide molecule are conserved. These peptides can be obtained according to the instructions in the paragraph herein before.

The peptides according to the invention may have  
 10 all the optically active amino acid residues in L or D form, or some of the amino acid residues are in L and others are in D form.

By "substantially increasing the immunogenicity of a poorly immunogenic antigen molecule" it is meant to  
 15 comprise both the induction of an increase in the level of antibodies against said antigen as well as the presentation of said antibodies as mainly of the IgG isotype.

The peptide carrier may be linked to the antigen molecule directly or through a spacer.

20 A direct link between the peptide and Vi or Vi-fragments is shown in Scheme 1 herein, where the conjugate



30 is obtained by Procedure 1 as described hereafter.

The spacer may have the formula  $-O-R-CO$  or  $-NH-R-CO$ , thus forming an ester or amide, respectively, with the carboxyl group of Vi or Vi-fragments and a peptide bond with the terminal amino group of the peptide; or  $-NH-R-CH_2-$ ,  
 35 wherein R is a saturated or unsaturated hydrocarbon chain optionally substituted and/or interrupted by one or more

aromatic radicals or by heteroatoms such as O, S or N.  
Preferably, R is an aliphatic hydrocarbon chain containing 3-16 carbon atoms, such as the residue of  $\epsilon$ -aminocaproic acid.

5

10

15


20

25


30

35

Scheme 1:



The conjugate of the formula:



10 in which Ac is acetyl, AC is the residue of  $\epsilon$ -aminocaproic acid, Pep is the residue of the peptide carrier 278e or an analog thereof and the saccharide residue represents a repeating unit of the Vi capsular polysaccharide (Vi or vi-  
15 fragments) of *Salmonella typhi*, may be prepared by Procedure 2 depicted in Scheme 1 and described in detail hereafter.

The conjugates wherein the spacer is  $\text{-NH-R-CH}_2\text{-}$  are obtained by reduction of  $\text{-NH-R-CO-}$  groups or by alkylation of the peptidic amino terminus with  $\text{-NH-R-CH}_2\text{-X}$ , when X is an  
20 appropriate leaving group such as an halide.

The invention further relates to vaccines comprising a conjugate of the invention. These vaccines may be administered by any suitable route, e.g., orally or via the subcutaneous route in suitable vehicles for human and  
25 veterinary purposes.

The invention will now be illustrated by the following non-limiting examples:

### 30 EXAMPLES

In the examples, the following materials and methods will be used.

#### Materials & Methods

35 a. Materials: All solvents and chemicals were of analytical grade and obtained from Aldrich, U.S.A., unless otherwise mentioned.

b. Peptide synthesis: Peptide 278e was prepared with an automated synthesizer (Applied Biosystem model 430A, Germany) using the company's protocols for t-butyloxycarbonyl (BOC) strategy (Kent et al, 1984).

5 The following control peptides were synthesized: Peptide 278h corresponding to positions 458-474 of the human hsp65 molecule, 278m corresponding to positions 458-474 of the murine hsp65, and 278cox corresponding to positions 437-453 of the Coxiella burnetii hsp65 protein, said control

10 peptides having the sequences depicted below:

|        |                                   |
|--------|-----------------------------------|
| 278h   | N E D Q K I G I E I I K R T L K I |
| 278m   | N E D Q K I G I E I I K R A L K I |
| 278cox | N E D Q R V G V E I A R R A M A Y |

A further control peptide, AcR259-271, corresponds to positions 259-271 of the murine acetylcholine receptor  $\alpha$ -chain and has the sequence:

V I V E L I P S T S S A V

This peptide is recognized by T cells in the context of MHC class II molecules of the H-2d haplotype.

20 c. Reversed-phase HPLC: The purity of the peptide products was estimated by using the analytical HPLC column RP18 (Merck, Darmstadt, Germany) employing the SP8750 liquid chromatography system equipped with a SP8733 variable wavelength detector in water-acetonitrile gradients

25 containing 0.1% trifluoroacetic acid (TFA). The effluents were monitored by UV absorbance at 220 nm. Acetonitrile of HPLC grade was purchased from Merck (Darmstadt, Germany). Peptides were further analyzed by amino acid analysis.

d. Vi: The Vi purified from Citrobacter freundii

30 WR7011 (kindly donated by J.B. Robbins and S.C. Szu, National Institute of Health, Bethesda, Maryland, U.S.A.) contained < 1% (each) protein, nucleic acid, and lipopolysaccharide. The molecular size of the Vi was estimated to be  $3 \times 10^3$  kD. The Vi-fragments of about 45kD were prepared by ultrasonic

35 irradiation and were kindly provided by Dominique Schulz (Pasteur-Merieux, France).

**e. Coupling of Vi and Vi-fragments with peptide:**

Procedure 1 (see scheme 1) Conjugation of Vi/Vi-fragments and peptide without a spacer. One part of Vi/Vi-fragment and one part of peptide were dissolved in a minimal  
5 volume of double distilled water (ddw) and incubated for 12 hours at room temperature (RT) at pH 6 in the presence of two parts water-soluble carbodiimide (CDI; 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride). After dialysis of the reaction mixture, the peptide density  
10 in the conjugate was determined by amino acid analysis and the sugar content of the construct estimated by Fourier transformed infrared spectroscopy (FTIR).

Procedure 2 (see scheme 1) Coupling of Vi/Vi-fragments and peptide following extension of peptide chain by a spacer  
15 in solution. In order to activate the carboxyl-function of the tBoc- $\epsilon$ -aminocaproic acid (t-Boc-AC) by N-hydroxysuccinimide, 1 mmol t-Boc-AC was mixed with 1.15 mmol N-hydroxysuccinimide in a minimal volume of dioxane (Merck, Germany); 1.15 mmol N,N'-dicyclohexylcarbodiimide (DCC)  
20 dissolved in dioxane was added, and after 3 hours the reaction mixture was filtered and washed with dioxane. 0.1 mmol of the desired peptide was dissolved in a small amount of ddw and mixed with 0.2 mmol  $\text{KHCO}_3$ , (Merck). The solution, in dioxane, of the N-hydroxysuccinimide ester of t-BocAC and  
25 the prepared peptide solution were mixed and reacted for 1 hour with vigorous mixing. The reaction mixture was then diluted with ddw (10 ml), cooled and acidified with 1N  $\text{KHSO}_4$ , solution. The product was extracted by ethyl acetate. The organic solution was washed with ddw, dried over  $\text{Na}_2\text{SO}_4$ , and  
30 evaporated to dryness. After drying the product for 2 hours over  $\text{P}_2\text{O}_5$ , dissolving it with 4-5 ml TFA and reacting for 10 minutes, the liquid was evaporated in vacuum at  $30^\circ\text{C}$ . The compound was washed twice with  $\text{CH}_2\text{Cl}_2$  and the fluid evaporated before drying 2-3 hours over  $\text{P}_2\text{O}_5$ . Subsequently, the peptide-  
35 AC product was dissolved in ddw and the pH adjusted to 8. Five mg N-hydroxysuccinimide ester (prepared as described in



Procedure 2 of Patent Application No. 102687) of Vi/Vi-fragments were added. After several hours of incubation, the resulting Vi-AC-Peptide conjugate was dialysed against ddw. The peptide density in the conjugate was estimated by amino acid analysis.

f. Immunization: Female mice belonging to different strains, 2-3 months old, were immunized subcutaneously (sc), two times 4 weeks apart with Vi/Vi-fragment alone or the Vi/Vi-fragment-conjugate. The injected amount of antigen varied from experiment to experiment and is indicated in the figures. The used adjuvant was in all cases IFA. Mice from each experimental group were bled 12 days after each injection.

g. Serology: Vi/Vi-fragment antibody levels elicited in mice with native or conjugated Vi, were determined by an enzyme-linked immunosorbent assay (ELISA). Since negatively-charged polysaccharides do not attach well to the polystyrene commonly used in the solid-phase ELISA, positively charged methylated bovine serum albumin (BSA) was used to coat Vi/Vi-fragments on the solid surface with very little non-specific binding. In detail, 0.5 mg Vi were dissolved in 1 ml PBS and stirred for 1 hour at room temperature. Ten mg methylated BSA (Sigma) were suspended in 1 ml H<sub>2</sub>O and the obtained solution filtered on a 0.8 µm filter. To prepare the coating solution, 1 ml of dissolved polysaccharide was stirred for 20 minutes at room temperature with 50 µl of the methylated BSA solution and subsequently diluted 1:20 in PBS. Nunclon delta Si microwell plates were coated for 3 hours at 37°C with 100 µl coating solution per well (2.5 µg Vi/well). The plates were washed five times with PBS containing 0.33% Brij35 (Sigma) and blocked with a solution of PBS and 1% dried skimmed milk for 2 hours at 37°C. After washing, 100 µl aliquots of diluted unknown sera and of diluted standard serum (dilution buffer containing 1% skimmed milk and 0.33% Brij35 in PBS) were added and the plates were incubated for 1 hour at 37°C. Reference and test sera were applied to the plates in duplicate. The non-bound antibodies were removed

by washing and a 1:5000 dilution of goat anti-mouse IgG Fab<sub>2</sub>-alkaline phosphatase conjugate (Sigma), in the case of the test sera, and rabbit anti-horse IgG Fab<sub>2</sub> enzyme conjugate, in the case of the standard serum, was added to the plates  
5 (100 $\mu$ l/well). After an incubation of 2 hours at 37°C, the plates were washed and the bound antibody visualized by the addition of 100  $\mu$ l substrate solution containing 0.6 mg/ml of p-nitrophenylphosphate (Sigma) in diethanolamine-H<sub>2</sub>O pH 9.8. The enzyme reaction was stopped 20 minutes later by the  
10 addition of 10  $\mu$ l 5N NaOH per well. Optical densities were read at 405 nm. The anti-Vi standard serum Burro 260, containing 550mg Vi antibody/ml, was prepared by multiple intravenous injections of formalin-fixed Salmonella typhi Ty2 (kindly donated by J.B. Robbins and S.C. Szu, NIH, Maryland,  
15 U.S.A.). The results obtained are expressed as optical density read at 405 nm.

**h. Lymph node Proliferation after peptide-immunization:**

Groups of 3 mice of the designated mouse strain were immunized sc into the footpads with 20  $\mu$ g peptide  
20 emulsified in 0.2 ml IFA/PBS (0.1 ml/foot). Draining lymph nodes were taken 10 days later. Lymph node cells (LNC) of immunized mice 5 X 10<sup>6</sup>/well) were cultured in the presence of different antigens. Cultures were set up in 200  $\mu$ l Eagles medium supplemented with 2 mM glutamine, nonessential amino  
25 acids, 1mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin, 5 x 10<sup>-5</sup>M  $\beta$ -mercaptoethanol (Fluka AG, Buchs, Switzerland) containing 1% of syngeneic normal mouse serum, in round bottom microtiter plates (Falcon). After four-five  
30 days incubation, <sup>3</sup>H-thymidine (0.5 mCi of 5 Ci/mmol, Nuclear Research Center, Negev, Israel) was added. Sixteen hours later, cells were harvested and radioactivity was counted. Results are expressed as counts per minute (cpm) or as stimulation indices (SI). The SI was defined as the ratio of the mean cpm of test cultures (with antigen) and the mean cpm  
35 of control cultures (without antigen).

### Examples

#### **EXAMPLE 1.      Preparation of Vi-peptide conjugates**

Conjugates of Vi/Vi-fragments with peptide 278e and  
5 the control peptides were prepared as described above.

The composition of the Vi-peptide conjugates is  
summarized in Table 1. The results presented in Table 1  
indicate that the molar ratio of peptide per sugar monomer  
was variable. Peptide doses of 0.8-2.2  $\mu$ g injected per mouse  
10 as sugar-peptide conjugate were shown to be most effective.

#### **EXAMPLE 2.      Lymph node cell proliferation to peptide 278e in different mouse strains with varying major histocompatibility complex MHC) background.**

2.1. Lymph node proliferation after immunization  
15 with free carrier peptide. In order to test if peptide 278e  
can be recognized by the immune system in the context of  
different alleles of the murine MHC, 2-3 month old female  
mice (three animals per group) were injected sc with 20  $\mu$ g of  
20 free peptide 278e emulsified in IFA as described in Material  
& Methods herein and specific proliferation of lymph node  
cells to peptide 278e and control peptides.

As shown in Fig. 1, LNCs of BALB/c (H-2d) mice  
inoculated with peptide 278e showed clear specific  
25 proliferative responses to the latter whereas no  
proliferation occurred to control peptide 278m and 278cox.  
Thus, LNCs primed with peptide 278e do not cross-react with  
the homologous self-peptide 278m derived from the sequence of  
murine hsp65.

30 Fig. 2a-c demonstrates that peptide 278e was also  
recognized in the three different congenic B10 mouse strains.  
LNCs of B10.RIII mice (H-2') (Fig. 2a), B10.BR mice (H-2<sup>k</sup>)  
(Fig. 2b) and B10.S mice (H-2<sup>s</sup>) (Fig. 2c) showed significant  
higher proliferative responses to peptide 278e in the  
35 designated peptide concentrations than to the control peptide  
AcR259-271.

2.2. Lymph node cell proliferation to peptide 278e after immunization with peptide 278e conjugated to Vi-fragments. To analyze if coupling of peptide 278e to the polysaccharide Vi-fragments changes its antigenic structure, the LNC response to the peptide alone was tested after immunization with the sugar-peptide conjugate. Fig. 3 and Fig. 4 distinctly show that LNCs elicited by Vi-fragments-278e in BALB/c mice can recognize the unconjugated peptide when immunized with 2  $\mu$ g Vi-fragments/mouse (Fig. 3) or 20  $\mu$ g Vi-fragments/mouse (Fig. 4) as sugar-peptide conjugate (for the belonging injected peptide amount see Table 1).

Table 1

|    |                               |                                                              |
|----|-------------------------------|--------------------------------------------------------------|
| 15 | Vi-fragment-peptide conjugate | Peptide amount injected per 2 $\mu$ g Vi-fragment [ $\mu$ g] |
|    | Vi-fragments-278e             | 0.8                                                          |
|    | Vi-fragments-278m             | 1.8                                                          |
|    | Vi-fragments-278h             | 2.2                                                          |

20

**EXAMPLE 3. Antigenicity of Vi-fragments conjugated to peptide 278e.** To examine if peptide 278e conjugated to Vi-fragments can enhance the immune response to this T-ind antigen, the immune response to the sugar was studied after inoculation of five BALB/c mice with the sugar-peptide conjugate. Fig. 5 clearly demonstrates that peptide 278e covalently linked to Vi-fragments can enhance the sugar-specific IgG antibody production substantially. Immunizing mice with a second dose of the conjugate gave rise to a strong booster effect indicating the involvement of T cells in the sugar-specific immune response. Inoculating BALB/c mice with the unconjugated polysaccharide only induced negligible levels of specific antibodies. The immune response induced by Vi-fragments-278e is compared to that elicited by the sugar conjugated to peptide 278h and 278m.

The above experiments offer evidence that peptide 278e can be recognized in association with a wide range of

alleles of murine MHC molecules and can be used as carrier epitope for inducing enhanced immune responses to poorly immunogenic molecules. This evidence may be summarized as follows:

5 (i) Primed LNCs of mouse strains with varying genetic MHC-background were able to recognize peptide 278e by exhibiting specific proliferative responses.

(ii) Conjugating peptide 278e to Vi-fragments did not change its antigenic structure since LNCs primed with  
10 278e coupled to the polysaccharide were still able to recognize the unbound peptide in an in vitro lymph node proliferation assay.

(iii) The immunogenicity of the Vi-fragments was increased when presented to the immune system as a  
15 conjugate coupled to peptide 278e.

The fact that LNCs that were primed with peptide 278e were not cross-reacting with the mouse homologue peptide 278m, indicates that peptide 278e used as carrier epitope probably will not induce immune responses directed to self  
20 components.

Since the immune response to peptide 278e seems not to be genetically restricted in mice, this synthetic peptide and analogs thereof might be used as universal carriers for the preparation of immunogenic conjugates to provide  
25 protective immunity against different pathogenic agents and can be suitable for the development of synthetic vaccines.

30

35

REFERENCES

- Avery, O.T. and Goebel, W.F., J. Exp- Med. 50:533-550 (1929)
- Babbitt, B. et al., Nature, 317:359-361 (1985)
- 5 - Barrios, C., et al., Eur. J. Immunol. 22:1365-1372 (1992)
- Brett, S., J., Cease, K., B., & Berzofsky, J. A., J. Exp. Med., 168:357-373 (1988)
- 10 - Herzenberg, L. A. & Tokuhisa T., J. Exp. Med., 155:1730-1740 (1982)
- Kappler, J., Roehn N., & P. Marrack, Cell, 49, -(1987)
- Kent, S. B. H., Hood, L. E., Beilan, H., Maister, S., & T. Geiser, Peptides by U. Ragnarsson, Stockholm (1984)
- 15 - Lussow, A. R. et al., Immunol. Letters 25:255-263 (1990)
- Lussow, A. R. et al., Eur. J. Immunol. 21:2297-2302 (1991)
- Munk, M.E. et al., Eur. J. Immunol. 18:1835-1838 (1988)
- 20 - Perraut, R., Lussow, A.R., Gavaille, S., Garraud, O., Matile, H., Tougne, C., van Embden, J., van der Zee, R. Lambert, P.-H., Gysin, J., & G. Del Giudice, Clin. Exp. Immunol., 93:382-386 (1993)
- Stone, A. L., & Szu S.C., J. Clin. Microbio., 26:719-725 (1988)
- 25 - Young, D. et.al., Proc. Natl. Acad. Sci. USA 85:4267-4270 (1988)

30

35

CLAIMS

1. A conjugate of a poorly immunogenic antigen and a synthetic peptide carrier constituting a T cell epitope  
5 derived from the sequence of *E. coli* hsp65 (GROEL), or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen.

10 2. A conjugate according to claim 1 wherein the synthetic peptide or analog is covalently bound to the poorly immunogenic antigen.

3. A conjugate according to claim 1 or 2 wherein  
15 the poorly immunogenic antigen is a peptide, a protein or a polysaccharide.

4. A conjugate according to claim 3 wherein the poorly immunogenic peptide is derived from HIV virus or from  
20 malaria antigen.

5. A conjugate according to claim 3 wherein the poorly immunogenic polysaccharide is a bacterial polysaccharide.

25

6. A conjugate according to claim 1 wherein the synthetic peptide carrier, herein designated Pep278e, corresponds to positions 437-453 of the *E. coli* hsp65 molecule, having the sequence:

30

4 3 7

4 5 3

N E D Q N V G I K V A L R A M E A.

7. A conjugate according to claim 1 wherein the  
35 synthetic peptide carrier or analog is directly bound to the poorly immunogenic antigen molecule.

8. A conjugate according to claim 7 wherein the poorly immunogenic antigen molecule is a bacterial polysaccharide.

5 9. A conjugate according to claim 8 wherein the bacterial polysaccharide is the capsular polysaccharide (CPS) Vi of Salmonella typhi.


10 10. A conjugate according to claim 1 wherein the synthetic peptide carrier or analog is linked to the poorly immunogenic antigen molecule through a spacer, selected from -O-R-CO-, NH-R-CO-, NH-R-NH-, O-R-NH- or -NH-R-CH<sub>2</sub>-, in which R is a saturated or unsaturated hydrocarbon chain optionally substituted and/or interrupted by one or more aromatic radicals or by heteroatoms selected from N, O or S.

11. A conjugate according to claim 10 wherein R is an aliphatic hydrocarbon chain containing 3-16 carbon atoms.

20 12. A conjugate according to claim 11 wherein R is the residue of  $\epsilon$ -aminocaproic acid.

13. A conjugate according to claim 12 of the formula

25



30

35 in which Ac is acetyl, Ac is the residue of  $\epsilon$ -aminocaproic acid, Pep is the residue of the peptide carrier Pep278e and the saccharide residue represents a repeating unit of the Vi capsular polysaccharide of Salmonella typhi.



14. A conjugate according to any of claims 1 to 13 able to produce a T lymphocyte helper effect resulting in an immune response characteristic for T-dependent antigens.

5 15. A conjugate according to any of claims 1 to 13 which on reinjection elicits a booster response resulting in increase in the level of antibodies to the poorly immunogenic antigen molecule.

10 16. A conjugate according to claim 15 which induces antibodies mainly of the IgG isotype.

17. A vaccine comprising a conjugate as claimed in claim 1.

15

18. A method for enhancing the immunogenicity of a poorly immunogenic antigen molecule which comprises linking it to a synthetic peptide carrier constituting a T cell epitope derived from the sequence of *E. coli* hsp65, or an analog thereof, said peptide or analog being able to increase substantially the immunogenicity of the poorly immunogenic antigen molecule.

19. A method for enhancing the immunogenicity of a poorly immunogenic antigen molecule which comprises mixing it to a synthetic peptide carrier constituting a T cell epitope derived from the sequence of *E. coli* hsp65, or an analog thereof, said peptide or analog being able to increase substantially the immunogenicity of the poorly immunogenic antigen molecule.

20. A method according to claim 18 to 19 for enhancing the immunogenicity of bacterial polysaccharides.

21. A method for immunization of a mammalian host which comprises administering to said host an effective amount of a conjugate of claim 1.

22. A method for immunization of a mammalian host which comprises co-administering to said host effective amounts of a poorly immunogenic antigen molecule and of a synthetic peptide carrier constituting a T cell epitope  
5 derived from the sequence of *E. coli* hsp65, or an analog thereof, said peptide or analog being able to enhance substantially the immunogenicity of the poorly immunogenic antigen.

10

15

20

25

30

35




FIG. 1




FIG. 2c




FIG. 2b




FIG. 2a





FIG. 3



IMMUNOGEN

FIG. 4




FIG. 5

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/06575

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 424/184.1, 185.1, 193.1, 197.11, 257.1; 530/300, 350, 403

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 185.1, 193.1, 197.11, 257.1; 530/300, 350, 403

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Examiner's heat shock protein and adjuvant file references.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Automated Patent System (APS) and DIALOG (file BIOCHEM) key words: heat shock protein, GroEL, carrier, conjugat?, epitope.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                                                         | Relevant to claim No. |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Y         | Immunology Letters, vol. 25, issued 1990, A. R. Lussow et al., "Towards vaccine optimization", pages 255-264, see entire document.                                         | 1-22                  |
| Y         | Proc. Nat'l. Acad. Sci., vol. 85, issued June 1988, D. Young et al., "Stress proteins are immune targets in leprosy and tuberculosis", pages 4267-70, see entire document. | 1-22                  |



Further documents are listed in the continuation of Box C.



See patent family annex.

|                                                                                                                                                                         |     |                                                                                                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| * Special categories of cited documents:                                                                                                                                | *T  | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                                              |
| *A* document defining the general state of the art which is not considered to be of particular relevance                                                                | *X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                                                                     |
| *E* earlier document published on or after the international filing date                                                                                                | *Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *Z* | document member of the same patent family                                                                                                                                                                                                    |
| *O* document referring to an oral disclosure, use, exhibition or other means                                                                                            |     |                                                                                                                                                                                                                                              |
| *P* document published prior to the international filing date but later than the priority date claimed                                                                  |     |                                                                                                                                                                                                                                              |

Date of the actual completion of the international search

17 JULY 1995

Date of mailing of the international search report

07 SEP 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THOMAS CUNNINGHAM

Telephone No. (703) 308-0196



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/06575

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 38/04, 39/00, 39/108, 39/385; C07K 9/00, 14/245, 17/00, 19/00

**THIS PAGE BLANK (USPTO)**